Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
Dana-Farber Cancer Institute, Boston, Massachusetts.
David
D
Liu
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Elizabeth R
ER
Plimack
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
Jean
J
Hoffman-Censits
Dana-Farber Cancer Institute, Boston, Massachusetts3Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge.
Levi A
LA
Garraway
Dana-Farber Cancer Institute, Boston, Massachusetts.
Joaquim
J
Bellmunt
Dana-Farber Cancer Institute, Boston, Massachusetts3Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge.
Eliezer
E
Van Allen
Memorial Sloan Kettering Cancer Center, New York, New York.
Jonathan E
JE
Rosenberg
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015331:Cohort Studies; D006801:Humans; D009130:Muscle, Smooth / Q000473:pathology; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D011379:Prognosis; D015203:Reproducibility of Results; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*
D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human